Drug intelligence / Profile preview

atorvastatin + pravastatin

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination of two HMG-CoA reductase inhibitors (statins) that is generally not recommended for standard clinical use due to overlapping mechanisms and increased risk of side effects. Limited research suggests it may be beneficial in specific cases of heterozygous familial hypercholesterolaemia (HFH) patients who experience liver toxicity with higher doses of single statins. The combination (20 mg/day atorvastatin plus 40 mg/day pravastatin) was administered for approximately one year in a small study, showing beneficial effects on lipid parameters without causing hepatotoxicity.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on atorvastatin + pravastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atorvastatin + pravastatin.

Explore the full profile